• Program

• Block Program

• Speakers

PROGRAM QUESTIONS?

Robert Lee Kilpatrick
Partner

Phone:
+1.831.464.4230

3:00-6:30  Early Registration & Check-In - Meritage Lobby

Visit the registration desk to check-in on Tuesday, which allows you to jump-start your networking opportunities at the Opening Drinks Reception in the Estate Wine Cave.

By registering early, you'll be able to collect your name badge, program booklet, and handbag materials as well as avoid long lines on Wednesday morning.

5:00-6:30  Opening Drinks Reception - Estate Wine Cave

You are invited to attend the Opening Drinks Reception, sponsored by Deloitte Recap, in the Estate Wine Cave at the Meritage Resort. Connect with fellow delegates before C21 BioVentures begins, over drinks and appetizers. The beautiful natural stone and dark woods combined with Old World Florentine architecture and furnishings will offer you a networking environment unlike any other.

8:30-4:30  Registration - Meritage Lobby

8:30-10:30  Continental Breakfast - Vineyard Terrace

Join us for a refreshing continental breakfast of fresh fruit juices, muffins and pastries. Freshly brewed coffee, decaffeinated coffee, breakfast and herbal teas will also be available.

9:00-9:15  Welcoming Remarks - TVG - Salons VII - X

Title: Defining The New Reality: Business Models That Thrive And Prosper

C21 BioVentures was established in 1999, which was a very different time in the history of the life science industry. Fourteen years ago there was money for many new ventures. In fact, there were actually more venture capitalists then, and many of these were actively creating and developing life science companies. Here, in the greater Silicon Valley region we have seen enormous innovation, and the creation of many of the most important technology companies ever created: Google, Apple, Yahoo, Genentech, etc. Crucial to the innovation ecosystem called Silicon Valley is the rise and fall of companies: the building up, as well as destruction, of technology companies, as waves of innovation drive some to greater success, and wash over others whose business models are no longer competitive. Certainly in 2012 there is a new reality for technology companies everywhere in the world. New financial realities require companies to focus on their core businesses, and new technologies present fresh opportunities, and also competitive threats. Looking back to at least 2009, it is clear that the rules governing the creation and sustainability of life science companies have changed, and yet there are success stories to talk about - companies, and their investors, who have been able to navigate the new reality. Many of them are attending C21 2012. We will listen to their stories, in some cases formally presented at the podium, or during a business meeting, and also informally over a glass of fine wine. Thanks to the effort of so many people, including the C21 Advisory Board, C21 remains one of the most intimate gatherings of its type in the world, bringing together professional investors, with life science company CEOs and business development people, as well as pharma executives searching for the next deal. In this place, for two days, we all gain access to the people who have been successful this year, and we will meet many who will make news in 2012/2013.

Speaker: Dr. Robert Lee Kilpatrick, Partner, TVG

9:15-10:15  Leadership Session - Deloitte Recap - Salons VII - X

Title: The Rise and Rise of the Corporate VC: How Old Players are Becoming New Players and Restructuring the Financing of the Life Science Industry

In keeping with the theme of this year’s C21 BioVentures conference, this session will explore a relatively new phenomenon that is changing how private life science companies are being funded. What is happening is that more and more pharma companies are creating venture capital arms for a variety of reasons. These include getting a financial return on investments, without any special access to technology or products; accessing early stage opportunities; looking for innovation trends, as well as searching for product and/or company acquisition candidates. At the same time, there are VCs and other investors who are founding companies specifically to be sold.

The venture world has changed all out of recognition in recent years, with many venture capitalists being forced from the life science space, or focused solely on late stage deals. Public markets are closed to all but the very best life science companies. What is certain is that pharma companies are using their financial resources in new ways, including working together in partnership with non-corporate VCs in a consortium, funding biotech companies directly, and acting singly or together in innovative ways. There is no doubt that the world of 2012 is not the world of 1999 when C21 was founded.

This session provides an opportunity to take a closer look at the various ways that corporate VCs are defining a new reality for biotech companies, through the creation of business models that thrive and prosper at a time when instability in the financial markets has become the norm.

Chair: Mr. Eric Walczykowski, Recap Business Leader, Deloitte Recap LLC
Speaker: Dr. Rajeev Dadoo, Partner, SR One
Speaker: Dr. Steven Kuemmerle, Head, Venture Investments, Abbott Biotech Ventures Inc.
Speaker: Dr. Nilesh Kumar, Director, Merck Serono Ventures
Speaker: Dr. Samuel Wu, Managing Director, MedImmune Ventures

9:30-5:30  Face-to-Face Meetings - powered by biopartnering.com - Salons I-III

All meetings scheduled through biopartnering.com will be held at the numbered tables in Salons I-III. Please visit the onsite Meeting & Message Desk for assistance.
Sponsored by:

10:15-11:00  Leadership Session - Versant Ventures - Salons VII - X

Title: Top Ten Ways You Know You're Not Connecting With That VC In Front Of You

Based on a late night television show, this session is hosted by a famous Life Science Venture Capitalist who will count down the top 10 things a biotech executive must know in order to have a productive meeting. Several guest VCs will join this session and comment on each of the 10 “must knows.” Being prepared is the key to success in business, as in life, and the information shared by leading VCs will help biotech executives be more successful in attracting investors. It is anticipated that this session will be highly interactive and a good time for the audience.

Chair: Mr. Brian Atwood, Managing Director, Versant Ventures
Speaker: Dr. Srini Akkaraju, Managing Director , New Leaf Venture Partners
Speaker: Dr. David Kabakoff, Executive Partner, Sofinnova Ventures, Inc.
Speaker: Mr. Carl Weissman, Managing Director, OVP Venture Partners

11:00-12:00  Leadership Session - DLA Piper LLP - Salons VII - X

Title: The Darwinian Imperative

 

These are tough times for life science, particularly emerging biotech companies, facing both a shortage of available capital and a lack of liquidity for investors, as well as regulatory and reimbursement challenges. Yet, in the face of such adversity, some companies have found ways to survive, and even to thrive and prosper.

Some observers say that these companies are a good example of the Darwinian thesis of "survival of the fittest," that the most strong members of the species are the ones who survive. In fact, what Darwin actually said was "In the struggle for survival, the fittest win out at the expense of their rivals because they succeed in adapting themselves best to their environment." Darwin’s focus was on adaptability and flexibility in the face of change, not just on being fit or strong, as the key to survival.

The panel, featuring veterans of change, will focus on creative and flexible strategies which have allowed some life science companies to come back from the brink, to survive--or to become better at predicting and avoiding--scientific/clinical trial failure, financing failure, and other crises.

The panel will focus on "lessons learned and experience gained," exploring the mindset it takes for management, the Board and investors to be flexible enough to recognize when change is needed and to take steps necessary to make that change, including cost-cutting, redirection and restructuring of the company and its product focus, and creative fund-raising strategies, in order to survive in the face of adversity.

 

Chair: Mr. Bruce W Jenett, Partner, DLA Piper US LLP
Speaker: Mr. Steven Engle, Chief Executive Officer, Averigon Consulting
Speaker: Dr. Susan Molineaux, Chief Executive Officer and President, Calithera Biosciences, Inc
Speaker: Mr. Oleg Nodelman, Partner and Portfolio Manager, BVF Partners LP
Speaker: Ms. Kim R Tsuchimoto, Chief Financial Officer, Treasurer and Secretary, Raptor Pharmaceutical Corp

12:00-12:30  Podium Presentations - Stream 1 - Salon VI

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, their key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

12:00 Amorfix Life Sciences Ltd. - Canada
12:15 Sutro Biopharma - USA

12:00-12:30  Podium Presentations - Stream 2 - Salon IV

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, their key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

12:00 Savara - USA
12:15 Del Mar Pharmaceuticals - Canada

12:15-1:00  Presenting Company Tabletop Meetings - Salon II

Companies will be available for informal face-to-face meetings for 30 minutes immediately following their presentation time.

Table Time	Table Assignment	Company Name
12:15-12:45	A B	Amorfix Life Sciences, Ltd. Savara
12:30-1:00	C D	Sutro Biopharma Del Mar Pharmaceuticals

12:30-1:30  Hot Buffet Lunch - Vineyard Terrace & Estate Wine Cave

Refresh yourself with a delicious lunch buffet.

1:30-2:30  Trends & Issues Session - Latham & Watkins LLP - Salons VII - X

Title: Life Sciences Partnering Trends and Issues 2012

 

Our panel of experienced dealmakers will discuss life sciences partnering deal trends and issues from the last year, provide perspectives on the drivers for these trends and issues, and identify the opportunities and complexities resulting from the current environment. Topics will range from collaborations for development of biosimilars, partnering deals structured to preserve M&A opportunities and/or attract potential M&A suitors, and alliances designed to meet near-term funding or other specific strategic objectives.

 

Chair: Mrs. Judith Hasko , Partner, Latham & Watkins LLP
Chair: Mr. John Wehrli , Partner, Latham & Watkins LLP
Speaker: Mr. Steven James, President and Chief Executive Officer, KAI Pharmaceuticals, Inc.
Speaker: Mr. Stu Mackey, Executive Director and Deputy General Manager, Biosimilars, Amgen Inc.

2:30-5:15  Podium Presentations - Stream 1 - Salon VI

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, their key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

2:30 Accelerator Corporation - USA
2:45 Accelerator Corporation - USA
3:00 Auspex Pharmaceuticals - USA
3:15 VetDC, Inc. - USA
3:30 Zymeworks - Canada
3:45 Sernova Corp - Canada
4:00 Tobira Therapeutics, Inc. - USA
4:15 Numerate Inc. - USA
4:30 NewGen Therapeutics - USA
4:45 Salient Pharmaceuticals - USA
5:00 Open Monoclonal Technology, Inc. - USA

2:30-5:15  Podium Presentations - Stream 2 - Salon IV

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, their key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

2:30 ProNAi Therapeutics, Inc - USA
2:45 Pathway Therapeutics Inc - USA
3:00 StemPar Sciences - USA
3:15 Biognosys - Switzerland
3:30 Beta Cat Pharmaceuticals - USA
3:45 Incarda Therapeutics, Inc - USA
4:00 RiboMed Biotechnologies, Inc - USA

2:45-5:45  Presenting Company Tabletop Meetings - Salon II

Companies will be available for informal face-to-face meetings for 30 minutes immediately following their presentation time.

Table Time	Table Assignment	Company Name
2:45-3:15	D	ProNAi Therapeutics, Inc
3:00-3:30	E F	Accelerator Corporation Pathway Therapeutics Inc.
3:15-3:45	A B	Auspex Pharmaceuticals StemPar Sciences
3:30-4:00	C D	VetDC, Inc. Biognosys
3:45-4:15	E F	Zymeworks Beta Cat Pharmaceuticals
4:00-4:30	A B	Sernova Corp Incarda Therapeutics, Inc
4:15-4:45	C D	Tobira Therapeutics, Inc. RiboMed Biotechnologies, Inc
4:30-5:00	E F	Numerate Inc. Theraclone Sciences
4:45-5:15	A	NewGen Therapeutics
5:00-5:30	C	Salient Pharmaceuticals
5:15-5:45	E	Open Monoclonal Technology, Inc.

5:15-6:15  Presenter & Venture Capitalist Mixer
(by invitation only) - Salons VII - X

Title: Sponsored by BioQuest LLC

 

Podium Presenters will have the opportunity to mingle and network with Venture Capital Investors as well as get up close and personal with members of the C21 Advisory Board.

Additionally, the winner of the Biotech Rising Star Award will be revealed!

Contest Highlights:

1. Company recognition as an industry "up and comer"
2. Expert review by the C21 Advisory Board Rising Star Committee
3. Selection criteria based on business plan, market potential, investment interest, innovation, creativity and team member credentials
4. Award presentation and prize package to be presented immediately to the winner
5. Marketing and promotion to the TVG Global Life Science Network

Prize Package:

1. Complimentary user access to EvaluatePharma, TVG’s exclusive Pharmaceutical and Biotechnology industry data provider, for one Alpha access user for a period of four (4) months
2. Advisory Meeting at C21 BioVentures™ to include:
   
   - Legal Advisory Meeting with Bruce Jenett, Partner, Global Life Sciences Sector, DLA Piper
   - Venture Capital Advisory Meeting with Dr. Mahendra Shah, Venture Partner, ViVO Ventures
   - Communications Advisory Meeting with Cindy McGee, Vice President, Russo Partners LLC
3. Complimentary Podium Presentation at BioPartnering FutureEUROPE in Brussels, Belgium, October 2012
4. Marketing and Press Coverage through TVG Global Life Sciences Network and Social Media Channels

Sponsored by:

6:15-6:45  Transportation to Offsite Networking Reception - Front of Meritage Lobby

Coaches will transport delegates to the venue for the offsite networking reception at the Domaine Carneros winery.

Coaches will shuttle between the winery and the Meritage Resort until 8:30 PM, when the final coach will leave the reception for a return trip to the Meritage Resort.

No transportation or drop-offs will be provided to other locations.

6:30-8:30  Offsite Networking Reception - Domaine Carneros Winery

Join us for a relaxing evening of classic California wine, delicious hors d'oeuvres, and casual networking over exquisite views of vineyard-covered hills. Established in 1987, the Domaine Carneros Winery is considered a regional landmark.

Featured items on the menu will include; grilled zucchini with house-made ricotta, artisan cheese selections, alsatian onion tartlets with bacon and sage, ricotta and pork meatballs and crab and endive salad. In addition, there will be a creamy polenta station as well as a skewer station featuring chicken, lamb, beef and vegetables. The reception will have a sweet conclusion with chocolate sea salt tartlets.

The reception will include both indoor and outdoor networking spaces. Please dress warmly as the weather is often cool in the evening. Click here for directions.

8:30-4:00  Registration - Meritage Lobby

8:30-10:30  Continental Breakfast - Vineyard Terrace

Join us for a refreshing continental breakfast of fresh fruit juices, muffins and pastries. Freshly brewed coffee, decaffeinated coffee, breakfast and herbal teas will also be available.

9:00-9:45  Leadership Session - EvaluatePharma - Salons VII - X

Title: Watch the Money: Where We Are Making Investments, and Why

A group of VCs with active funds will talk about the life science companies they have made investments in, and explain their reasons for doing so. Practical examples of real investments will be reviewed. What attracted the VCs to the companies they have invested in? What criteria were used in the selection and vetting of candidates? What did it take to close the deal? Were the funded companies part of a trend (such as Hepatitis C investments), or one-off, best in class investments? Looking back, what made companies stand out that attracted an investment. Looking ahead, what types of investments is each VC on the panel looking for? Who will be next?

Chair: Ms. Debbie Paul, Senior Vice President North America, EvaluatePharma
Speaker: Dr. Doug Fisher, Principal, InterWest Partners
Speaker: Mr. Andrew Fontanini, Co-Founder and Managing Member, Pontifex Venture Partners
Speaker: Dr. Frank Torti, Principal, New Enterprise Associates

9:00-4:00  Face-to-Face Meetings - powered by biopartnering.com - Salons I-III

All meetings scheduled through biopartnering.com will be held at the numbered tables in Salons I-III. Please visit the onsite Meeting & Message Desk for assistance.
Sponsored by:

9:45-10:45  Trends & Issues Session - Prescience International, Inc. - Salons VII - X

Title: How Are Pharma Companies Driving Biotech Business Models? Change Today, Change Tomorrow and More Change to Come. What Does it All Mean?

Biotechnology companies are being shaped in ways that are very different from the past. Now, many investors create biotech companies to be sold to pharma companies. The idea that biotech companies will become fully integrated pharmaceutical companies, which was still fashionable a few years ago is now laughable. There is an awareness, at last among most investors, that biotech companies exist to serve big pharma, as part of what is now termed externalization of many R&D functions by big pharma companies. Seen from this perspective, big pharma is now undergoing a massive transformation that has been predicted for years – shedding many research and development projects (and the people working on them) in favor of partnerships with smaller focused biotech companies, who increasingly are being sourced on a global scale. In fact, externalization and globalization go hand and in hand, and this is now so common in the world of pharma, which has lagged behind other industries in this respect (IT, automotive, clothing, etc), that it goes unnoticed. Certainly, biotech CEOs are well aware that big pharma now really needs them more than ever. Big pharma is moving as fast as it can to access products and innovation from the smaller biotech companies. What is emerging is a changed industry. This panel will tell us what it looks like, today and over the next few crucial years of change.

Chair: Ms. Melinda Richter, Founder & Chief Executive Officer, Prescience International, Inc.
Speaker: Dr. Gaurav Aggarwal, Partner, Panorama Capital
Speaker: Dr. Don O'Sullivan, Head of Infectious Disease Partnering, Genentech, Inc
Speaker: Dr. Heather Preston, Managing Director, TPG Biotech
Speaker: Dr. Jim Schaeffer, Executive Director - Worldwide Licensing and External Research – West Coast, Merck Research Labs

10:45-12:30  Podium Presentations - Stream 1 - Salon VI

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, their key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

10:45 Inhibikase Therapeutics, Inc - USA
11:00 CalciMedica - USA
11:15 Applied Integrin Sciences, Inc. - USA
11:30 Theraclone Sciences - USA
11:45 Susavion Biosciences, Inc. - USA
12:00 NexDx, Inc. - USA
12:15 Vaxiion Therapeutics, Inc. - USA

11:00-1:00  Presenting Company Tabletop Meetings - Salon II

Companies will be available for informal face-to-face meetings for 30 minutes immediately following their presentation time.

Table Time	Table Assignment	Company Name
11:00-11:30	C	Inhibikase Therapeutics, Inc
11:15-11:45	E	CalciMedica
11:30-12:00	A	Applied Integrin Sciences, Inc.
12:00-12:30	E	Susavion Biosciences, Inc.
12:15-12:45	A	NexDx, Inc.
12:30-1:00	C	Vaxiion Therapeutics, Inc.

12:30-1:30  Hot Buffet Lunch - Vineyard Terrace & Estate Wine Cave

Refresh yourself with a delicious lunch buffet.

1:30-2:30  Leadership Session - TVG - Salons VII - X

Title: Big Vision VC’s: A Perspective from VC’s who have Survived and Thrived Through Sound Strategies, Tactics and Good Luck

Biotechnology appears to have lost its luster as an investment opportunity. It seems to be more difficult than ever before to get biotechnology companies funded. Yet, global demographics favor health-related investments, and technology companies have made a lot of money for many people. There are many success stories in the world of biotech, and yet the IPO window is nearly shut, and many VC firms have left the biotech space. What does this all mean? A panel of VC leaders has been assembled for one reason only: to hear the good, bad and the ugly from people who have survived many financial storms and remained successful as VCs focused on the biotech space. What do they see as drivers of innovation now and how can value creation become, again, something that moves biotech investments into the portfolios of many people. What is really going on, and what should investors be looking for in 2012/2013?

Chair: Dr. Robert Lee Kilpatrick, Partner, TVG
Speaker: Mr. Brian Atwood, Managing Director, Versant Ventures
Speaker: Dr. Timothy Mills, Managing Director, Sanderling Ventures
Speaker: Dr. Michael Ross, Managing Partner , SV Life Sciences

2:30-3:00  Podium Presentations - Stream 1 - Salon VI

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, their key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

2:30 Chelation Partners - Canada
2:45 TARIS Biomedical - USA

2:45-3:30  Presenting Company Tabletop Meetings - Salon II

Companies will be available for informal face-to-face meetings for 30 minutes immediately following their presentation time.

Table Time	Table Assignment	Company Name
2:45-3:15	E	Chelation Partners
3:00-3:30	A	TARIS Biomedical

3:00-4:00  Closing Session - Ferghana Partners - Salon VII - X

Title: The Half Billion Dollar Club: Biotechs That Have Survived and Thrived the Storm of 2011/2012

Financing for biotech companies has been tough by any measure during the last 18 months (all 2011 and 2012 to date); however there have been many success stories. CEOs of several biotechs that have survived and thrived in this time have come to C21 in Napa to share their experiences in raising financing. What they have achieved, and how they got their companies financed, is a compelling story, which will be shared with the C21 audience. There is no "one size fits all" financing model and these companies represent a variety of approaches because they were created by innovative entrepreneurs and now are at different stages of development. It is accurate to describe these companies as the very best illustrations of success - private biotech companies that have captured the attention and commitment of investors in one of the toughest markets on record. The Chairman of the panel is one of the industry's most experienced dealmakers and he has assembled this group to provide the audience access to the biotech CEOs who have successfully navigated the financial storm. The session will be followed by a drinks reception which allows for face-to-face discussions with the CEOs of these companies as well as some of the investors who have backed them.

 

Chair: Mr. Bill Kridel, Jr, Managing Director, Ferghana Partners Group
Speaker: Mr. William Lis, Chief Executive Officer, Portola Pharmaceuticals, Inc.
Speaker: Mr. Eric Loumeau, Chief Financial Officer, Rempex Pharmaceuticals, Inc
Speaker: Mr. Brian O'Callaghan, President and Chief Executive Officer, Sangart
Speaker: Mr. Clifford Stocks, Chief Executive Officer, Theraclone Sciences, Inc.

4:00-5:00  Closing Drinks Reception - Vineyard Terrace

An opportunity to say goodbye to fellow delegates and begin planning for C21 BioVentures 2013.